Hematopoietic Cell Patents (Class 424/173.1)
-
Publication number: 20100166777Abstract: The present invention relates to ex-vivo cells belonging to the hematopoietic system, characterized by the presence of MOSC-1 protein on cell surface, methods for isolating them and uses thereof.Type: ApplicationFiled: May 27, 2008Publication date: July 1, 2010Applicant: ISTITUTO NAZIONALE DI GENETICA MOLECOLARE-INGMInventors: Sergio Abrignani, Mariacristina Crosti, Monica Moro
-
Patent number: 7744888Abstract: Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as autoimmune diseases, transplant rejection, and allergic diseases.Type: GrantFiled: January 18, 2002Date of Patent: June 29, 2010Assignee: AbGenomics Cooperatief U.A.Inventors: Rong-Hwa Lin, Chung-Hsiun Wu, Pei-Ling Hsu
-
Publication number: 20100158901Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of autoimmune diseases and disorders in human subjects using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: ApplicationFiled: December 1, 2008Publication date: June 24, 2010Applicant: Duke UniversityInventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Publication number: 20100158903Abstract: The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.Type: ApplicationFiled: September 16, 2009Publication date: June 24, 2010Inventors: Craig Smith, Peter S. Chin
-
Patent number: 7740848Abstract: Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.Type: GrantFiled: September 2, 2008Date of Patent: June 22, 2010Assignee: Schering CorporationInventors: Robert A. Kastelein, Terrill K. McClanahan, Erin Murphy, Jason R. Chan
-
Patent number: 7740847Abstract: The present invention provides humanized anti-CD20 antibodies comprising a human IgG1 Fc region comprising an isoleucine at position 247 and a glutamine at position 339 as well as nucleic acids encoding the antibodies and methods of using the antibodies for treating lymphoma. Furthermore, the invention provides compositions comprising the antibodies and methods of producing them.Type: GrantFiled: July 18, 2005Date of Patent: June 22, 2010Assignee: Applied Molecular Evolution, Inc.Inventors: Barrett Allan, Weidong Jiang, Ying Tang, Jeffry Dean Watkins
-
Publication number: 20100150868Abstract: A method of individually optimizing a treatment for an inflammation associated disease is provided. The method comprising contacting each of identical white blood cell samples of a subject in need thereof with a different pharmaceutical agent of a plurality of pharmaceutical agents for the inflammation associated disease, so as to allow elicitation of an anti-inflammatory activity in the white blood cell samples; assaying the anti-inflammatory activity in the white blood cell samples; and identifying a pharmaceutical agent of the plurality of pharmaceutical agents eliciting a strongest anti-inflammatory activity, the pharmaceutical agent being the individually optimized treatment for the inflammation associated disease, wherein when the inflammation associated disease is multiple sclerosis the white blood cell samples are inflamed white blood cell samples. Methods of treating an inflammation associated disease are also described.Type: ApplicationFiled: March 21, 2006Publication date: June 17, 2010Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.Inventors: Anat Achiron, Michael Gurevich
-
Publication number: 20100151031Abstract: The presently disclosed invention is broadly directed to therapeutic micro- and/or nanoparticles designed to target an immune cell with an active agent. More particularly, the particles have a predetermined geometry and a broadest dimension of less than about 10 ?m. The immune cell-targeted micro and/or nanoparticles may additionally comprise a biocompatible polymer.Type: ApplicationFiled: March 24, 2008Publication date: June 17, 2010Inventors: Joseph M. DeSimone, Robby Petros, Jeffrey Frelinger, Adam Buntzman
-
Publication number: 20100150947Abstract: Provided are methods and compositions for the induction and maintenance of tolerance in hematopoietic stem cell allografts.Type: ApplicationFiled: December 16, 2009Publication date: June 17, 2010Applicant: The Cleveland Clinic FoundationInventor: Maria Z. Siemionow
-
Publication number: 20100150927Abstract: An objective of the present invention is to provide an antibody having a high cell death-inducing activity. To solve the above-described problems, the present inventors immunized mice with cells expressing human HLA class IA and human ?2 microglobulin (?2M) to obtain monoclonal antibodies. Screening of the obtained antibodies was performed to obtain ten clones of antibodies having a cell death-inducing activity. Analyses of these clones revealed that three of the clones (antibodies C3B3, C11B9, and C17D11), which have the ?2 domain of the HLA class I antigen as an epitope, showed a stronger cytotoxic activity when crosslinked with an anti-mouse IgG antibody. Furthermore, when a C3B3 diabody was generated, this diabody was revealed to show a stronger anti-tumor effect compared with conventional diabodies of the 2D7 antibody, which is an HLA class IA antibody.Type: ApplicationFiled: July 13, 2007Publication date: June 17, 2010Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Naoki Kimura, Shigeto Kawai
-
Publication number: 20100150946Abstract: The present invention relates to prostate cancer markers, compositions comprising such markers, and methods of using such markers to induce or increase an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.Type: ApplicationFiled: August 24, 2009Publication date: June 17, 2010Applicant: Cell Genesys, Inc.Inventors: Karin Jooss, Thomas Harding, Minh Nguyen, Kathryn E. Koprivnikar
-
Publication number: 20100143347Abstract: The present invention concerns protection of an organ or tissue following an ischemic episode In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1 Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for exampleType: ApplicationFiled: January 11, 2008Publication date: June 10, 2010Inventor: J. Marc Simard
-
Patent number: 7731966Abstract: Monoclonal antibodies prepared against platelet ?3 integrin useful in antithrombotic therapy or in models of thrombosis, thrombocytopenia, and anti-angiogenesis. The antibodies are prepared using ?3 integrin deficient (?3?/?) mice immunized against platelets or ?3 integrin fragments.Type: GrantFiled: April 11, 2008Date of Patent: June 8, 2010Assignee: Canadian Blood ServicesInventors: Heyu Ni, Guangheng Zhu
-
Publication number: 20100136030Abstract: The present invention relates to antagonist antibodies directed against human OX40 receptor (CD134) and fragments thereof, including the amino acid sequences of antagonist antibodies and the nucleic acids that encode the antibodies. Also included in the present invention are antigen binding regions (CDRs) derived from the light and/or heavy chain variable regions of said antibodies. Another aspect of the present invention is the use of anti-OX40 antagonist antibodies in the treatment of inflammatory and autoimmune diseases. The present invention also relates to humanized sequences of an antagonist antibody A10 and epitope mapping of the binding site of the antibody.Type: ApplicationFiled: February 26, 2008Publication date: June 3, 2010Inventors: Lamhamedi-Cherradi Salah-Eddine, Yao Zhengbin, Singh Sanjaya
-
Publication number: 20100136029Abstract: The present invention relates to the use of a tri-substituted glycerol compound for the manufacture of a medicament for the treatment of hematological malignancies. The invention also refers to a kit-of-parts comprising such a medicament. Finally, the invention also relates to a corresponding method for the treatment of such conditions as well as to an in vitro method for determining the susceptibility of such malignant cells to a medicament as defined in the invention.Type: ApplicationFiled: November 9, 2007Publication date: June 3, 2010Applicants: UNIVERSITATSKLINIKUM HAMBURG-EPPENDORF, ALPHAPTOSE GMBHInventors: Axel Rolf Zander, Francis Ayuk Ayuketang, Wolfgang Richter, Lutz Weber
-
Patent number: 7727525Abstract: The present invention provides anti-CD20 antibody fragments for use as in vivo imaging probes and as therapeutic moieties for the diagnosis and treatment of NHL.Type: GrantFiled: April 27, 2007Date of Patent: June 1, 2010Assignees: City of Hope, The Regents of the University of CaliforniaInventors: Anna M. Wu, Tove Olafsen, Andrew A. Raubitschek
-
Publication number: 20100129361Abstract: The invention relates to methods of T cell immune system modulation and the treatment of immune system related diseases and disorders. In particularly, embodiments of the invention provides immunotherapeutics in the form of antibodies, bioengmeered antibodies and recombinant proteins for the treatment of autoimmune diseases and disorders, organ transplantation rejection, graft-versus-host tissue diseases, and T-cell based lymphoma and leukemia.Type: ApplicationFiled: May 1, 2008Publication date: May 27, 2010Applicant: THE BRIGHAM AND WOMEN'S HOSPITALInventors: I-Cheng Ho, Peter Kim, Sung-Yun Pai
-
Patent number: 7722874Abstract: Methods for inducing antigen-specific T cell tolerance are disclosed. The methods involve contacting a T cell with: 1) a cell which presents antigen to the T cell, wherein a ligand on the cell interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor on the surface of the T cell which inhibits interaction of the ligand on the antigen presenting cell with the receptor on the T cell. In a preferred embodiment, the cell which presents antigen to the T cell is a B cell and the receptor on the surface of the T cell which mediates contact-dependent helper effector function is gp39. Preferably, the antagonist is an anti-gp39 antibody or a soluble gp39 ligand (e.g., soluble CD40). The methods of the invention can be used to induce T cell tolerance to a soluble antigen or to an allogeneic cell.Type: GrantFiled: October 1, 1998Date of Patent: May 25, 2010Assignees: Trustees of Dartmouth College, University of Massachusetts Medical CenterInventors: Randolph J. Noelle, Teresa M. Foy, Fiona H. Durie
-
Publication number: 20100111940Abstract: Methods and compositions for treating patients (e.g., patients who are insulin resistant, patients who have diabetes, or are at risk for developing diabetes) are disclosed herein. The methods can include administration of an a1 antitrypsin (AAT) polypeptide or an agent, such as a nucleic acid molecule or organic compound, that promotes the expression or activity of a1-antitrypsin.Type: ApplicationFiled: September 12, 2007Publication date: May 6, 2010Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE GENERAL HOSPITAL CORPORATIONInventors: Jeffrey Flier, Maria Koulmanda, Terry B. Strom
-
Publication number: 20100111946Abstract: A method of inhibiting complement activation mediated by C3b inhibitors in a subject includes administering a C3B inhibitor to the subject to inhibit at least one of C3b binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of C3a, C5a, and MAC.Type: ApplicationFiled: March 19, 2008Publication date: May 6, 2010Inventor: Rekha Bansal
-
Publication number: 20100098689Abstract: The invention provides 4-IBBL blocking agents, as well as pharmaceutical compositions and articles of manufacture comprising such blocking agents as new therapeutic interventions for sustained inflammation. Thus, the invention also provides methods for reducing sustained production of tumor necrosis factor.Type: ApplicationFiled: October 16, 2007Publication date: April 22, 2010Applicant: The Scripps Research InstituteInventors: Young Jun Kang, Jiahuai Han
-
Patent number: 7695716Abstract: Methods of treating cancer and autoimmune and inflammatory diseases are provided.Type: GrantFiled: April 11, 2008Date of Patent: April 13, 2010Assignee: Seattle Genetics, Inc.Inventors: Jonathan G. Drachman, May Kung Sutherland, Eric Sievers, Grant Risdon, Alan Wahl, Tim Lewis
-
Publication number: 20100080814Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.Type: ApplicationFiled: September 17, 2009Publication date: April 1, 2010Applicant: Xencor, Inc.Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton
-
Publication number: 20100068180Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: ApplicationFiled: January 11, 2008Publication date: March 18, 2010Inventors: Vivienne S. Marshall, Richard A. Banas, Catherine J. Trumpower
-
Publication number: 20100055111Abstract: The present invention includes methods of enhancing immune responses by administering an inhibitor of indoleamine-2,3-dioxygenase (IDO) along with one or more inhibitors of the PD-1/PD-L pathway and/or one or more inhibitors of the CTLA4 pathway.Type: ApplicationFiled: February 14, 2008Publication date: March 4, 2010Applicants: Med. College of Georgia Research Institute, Inc., Regents of the University of MinnesotaInventors: Madhav D. Sharma, Bruce R. Blazar, Andrew L. Mellor, David H. Munn
-
Patent number: 7666422Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.Type: GrantFiled: January 20, 2009Date of Patent: February 23, 2010Assignee: Seattle Genetics, Inc.Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
-
Patent number: 7666421Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.Type: GrantFiled: December 5, 2005Date of Patent: February 23, 2010Assignee: Genetics Institute, LLCInventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
-
Publication number: 20100040614Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.Type: ApplicationFiled: December 26, 2007Publication date: February 18, 2010Inventors: Rafi Ahmed, Rama Amara, Gordon Freeman, Arlene Sharpe
-
Patent number: 7655230Abstract: A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.Type: GrantFiled: April 21, 2008Date of Patent: February 2, 2010Assignee: Genentech, Inc.Inventors: Martin M. Bednar, Cordell E. Gross, Linda J. Gross, legal representative, G. Roger Thomas
-
Patent number: 7651678Abstract: Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R? or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieites such as, for example, radioisotopes or chemotherapeutics.Type: GrantFiled: April 23, 2004Date of Patent: January 26, 2010Assignee: University of Kentucky Research FoundationInventor: Craig Jordan
-
Publication number: 20100015134Abstract: The present invention relates to a peptide, such as an antibody, capable of binding to CD4 and use thereof for the mediation of radiation treatment of a clinical condition. The radiation treatment may for instance by treatment with PUVA.Type: ApplicationFiled: August 18, 2006Publication date: January 21, 2010Inventors: Paul Parren, Ole Baadsgaard, Denis Alexander
-
Publication number: 20100008936Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: ApplicationFiled: March 16, 2007Publication date: January 14, 2010Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Publication number: 20100003252Abstract: The present application describes methods for blocking immune response to foreign antigens in a mammal using antagonists which bind to CD20.Type: ApplicationFiled: September 8, 2009Publication date: January 7, 2010Applicants: Genentech, Inc., Biogen Idec Inc.Inventors: Antonio J. Grillo-Lopez, Lori A. Kunkel, Mark D. Pescovitz
-
Publication number: 20090324615Abstract: The present invention provides methods of reducing or enhancing T cell activation and/or B cell activation in a subject, comprising administering to a subject an effective amount of an inhibitor or enhancer, respectively, of Semaphorin 6D (Sema6D) activity on T cells and/or B cells.Type: ApplicationFiled: March 23, 2007Publication date: December 31, 2009Inventors: Jenny P.-T. Ting, Brian P. O'Connor, So-Young Eun, Zhengmao Ye
-
Publication number: 20090304625Abstract: Provided are compositions and methods for modulating cardiac cell hypertrophy and hyperplasia using inhibitors of c-Kit activity.Type: ApplicationFiled: January 18, 2007Publication date: December 10, 2009Inventors: Ahsan Husain, Nawazish Naqvi, Robert M. Graham, Louis J. Dell'talia, Ming Li
-
Publication number: 20090304709Abstract: Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as autoimmune diseases, transplant rejection, and allergic diseases.Type: ApplicationFiled: June 29, 2009Publication date: December 10, 2009Applicant: AbGenomics Coöperatief U.A.Inventors: RONG-HWA LIN, CHUNG-HSIUN WU, PEI-LING HSU
-
Publication number: 20090304715Abstract: The present inventors generated modified antibodies in which several Fc domains are linked in tandem to the C terminus of the heavy chain, and modified antibodies in which Fc domains are linked in tandem via spacers, and measured the affinity for Fc receptors, CDC activity, and ADCC activity. A previous report indicated that CDC activity is not enhanced by linking multiple Fcs. However, the modified antibodies of the present invention exhibited enhanced ADCC activity. The methods of the present invention enable provision of antibody pharmaceuticals having a marked therapeutic effect.Type: ApplicationFiled: March 2, 2007Publication date: December 10, 2009Applicant: TOKYO UNIVERSITY OF SCIENCEInventors: Yasuhiko Masuho, Hiroaki Nagashima
-
Publication number: 20090297518Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.Type: ApplicationFiled: August 10, 2009Publication date: December 3, 2009Applicants: ONO PHARMACEUTICAL CO., LTD.Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
-
Publication number: 20090297479Abstract: The present invention relates to the use of DC-HIL and fragments and variants thereof to selectively target toxins to activated T-cells expressing a unique form of syndecan-4 that is not found on other cells. Thus, the toxin is delivered only to activated T-cells, and not to other syndecan-4 expressing cells. Such toxin-DC-HIL conjugates are useful in the treatment of T-cell inflammatory disorders such as dermatitis, autoimmune disease, and graft rejection, as well as T-cell lymphomas.Type: ApplicationFiled: March 26, 2009Publication date: December 3, 2009Inventors: Kiyoshi Ariizumi, Ponciano D. Cruz
-
Publication number: 20090291090Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.Type: ApplicationFiled: January 23, 2009Publication date: November 26, 2009Inventors: MARY G. HOFFEE, DANIEL TAVARES, ROBERT J. LUTZ
-
Publication number: 20090285834Abstract: The present invention relates to a memory CTL induction enhancer comprising a combination of substance (b) with substance (a) and/or substance (c), wherein substance (a) is an activator of antigen-presenting cells, substance (b) is an inducer of homeostatic proliferation after induction of lymphopenia, and substance (c) is a suppressor of regulatory T cells.Type: ApplicationFiled: November 21, 2006Publication date: November 19, 2009Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.Inventor: Hideyuki Tomizawa
-
Publication number: 20090285835Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.Type: ApplicationFiled: June 23, 2008Publication date: November 19, 2009Inventors: Shixin Qin, Nasim Kassam, Walter Newman
-
Publication number: 20090285752Abstract: The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicle and at least one conjugated antibody, wherein predosing with a non-radiolabeled antibody is not performed.Type: ApplicationFiled: May 18, 2009Publication date: November 19, 2009Applicant: IMMUNOMEDICS, INC.Inventors: David M. GOLDENBERG, Hans J. HANSEN
-
Patent number: 7618633Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: GrantFiled: September 25, 2007Date of Patent: November 17, 2009Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Publication number: 20090280082Abstract: The present invention relates to methods for treating autoimmune disorders. In an embodiment, the invention is directed to a method for treating an autoimmune disorder comprising administering a TCCR agonist. In an embodiment, the autoimmune disorder is at least partially mediated by a Th1 response. In an embodiment, the autoimmune disorder is at least partially mediated by CD8+ T-cell proliferation.Type: ApplicationFiled: February 27, 2009Publication date: November 12, 2009Inventors: Nico GHILARDI, Frederic DeSauvage
-
Patent number: 7611708Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.Type: GrantFiled: October 6, 2008Date of Patent: November 3, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Keting Chu, Lorianne K. Masuoka
-
Publication number: 20090269353Abstract: Stimulation of T cells to respond to self antigens is achieved through a blockade of CTLA-4 signaling. CTLA-4 blocking agents are combined with antigen preparations, either alone or with additional immune response stimulating agents, in costimulation strategies to break immune tolerance and stimulate an enhanced T-cell response against self antigens. This enhanced response is useful for the treatment of non-immunogenic and poorly-immunogenic tumors, as well as other medical conditions requiring selective tissue ablation.Type: ApplicationFiled: April 9, 2009Publication date: October 29, 2009Applicant: The Regents of the University of CaliforniaInventors: James P. ALLISON, Andrea Van Elsas, Arthur A. Hurwitz
-
Publication number: 20090263404Abstract: Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.Type: ApplicationFiled: April 4, 2008Publication date: October 22, 2009Inventors: Richard J. Bucala, Lin Leng, Christine N. Metz
-
Patent number: 7604800Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.Type: GrantFiled: May 10, 2005Date of Patent: October 20, 2009Assignee: AbGenomics Coöperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
-
Publication number: 20090258027Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules as well as gamma delta T cells. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, transplant and cell graft rejection, cancer, bacterial infection, HIV infection, and AIDS, as well as novel methods of diagnosis and of introducing a treatment regimen into a subject.Type: ApplicationFiled: January 28, 2008Publication date: October 15, 2009Applicant: The Regents of the University of ColoradoInventors: Martha Karen Newell, Evan Newell, Joshua Hunter Cabrera